GT Biopharma (GTBP) vs MetaVia (MTVA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
GT Biopharma is the larger company by market cap ($10.8 million vs $8.8 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GTBP | MTVA |
|---|---|---|
| Share price | $5.96 | $1.34 |
| Market cap | $10.75M | $8.83M |
| 1-day change | -3.87% | -8.22% |
| YTD return | +659.24% | — |
| 1-year return | +451.85% | — |
| 5-year return | -96.72% | — |
| EPS (TTM) | $-147.50 | $-3.65 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $28.75 | $14.85 |
| 52-week low | $4.91 | $0.966 |
| Distance from 52-week high | -79.27% | -90.98% |
| Analyst consensus | none | none |
| Avg. price target upside | +1158.39% | +1342.54% |
| Average volume | 55.55K | 230.88K |
| Shares outstanding | 1.80M | 6.59M |
| Employees | 1 | 8 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About GT Biopharma
GTBP stock →GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumors;and GTB-7550, a pre-clinical stage product candidate in development for the treatment of lupus and other autoimmune disorders.
Healthcare · Biotechnology · 1 employees
About MetaVia
MTVA stock →MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in Phase 1 trial for the treatment of obesity.
Healthcare · Biotechnology · 8 employees
GTBP vs MTVA FAQ
Which is bigger, GT Biopharma or MetaVia?
GT Biopharma (GTBP) is larger, with a market capitalization of $10.75M compared with $8.83M for MetaVia (MTVA).
Are GT Biopharma and MetaVia in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.